Roche announced CE label expansion of the VENTANA PD-L1 (SP263) Assay in non-small cell lung cancer (NSCLC) as a companion diagnostic for Tecentriq® (atezolizumab)....
CStone Pharmaceuticals, a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Pfizer Inc. announced that...
PharmaMar and partner Jazz Pharmaceuticals plc announced the initiation of a confirmatory Phase 3 clinical trial, LAGOON, evaluating Zepzelca® (lurbinectedin) for the treatment of...
